{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:00:23Z","timestamp":1776726023386,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Wild-type <jats:italic>KIT<\/jats:italic> and <jats:italic>PDGFRA<\/jats:italic> gastrointestinal stromal tumors (GIST) are rare tumors with limited treatment options. We sought to determine the clinicopathologic features of wild-type GIST and identify factors that influence overall survival (OS) using a large national database. Retrospective evaluation of patients with wild-type GIST in the National Cancer Database (NCDB) was performed. Demographic, clinicopathologic, and treatment data were analyzed. Features associated with OS were investigated using Kaplan\u2013Meier analysis and Cox proportional hazards model. 244 patients with median diagnosis age of 59\u00a0years (95% CI 57\u201363) were identified. The stomach was the most common primary site (57%) followed by the small intestine (35%). Surgical resection was performed on 85% of patients and 53% of patients received systemic therapy. Factors associated with decreased OS on multivariable analysis included small intestine primary (HR 2.72, 95% CI 1.13\u20136.69, <jats:italic>P<\/jats:italic>\u2009=\u20090.026) and\u2009&gt;\u20095 mitoses per 50 HPF (HR 4.77, 95% CI 1.86\u201313.2, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Wild-type GISTs may be identified in older patients, with most arising in the stomach and small bowel. Surgery remains the principal treatment modality. Small intestine primary site and high mitotic count were associated with abbreviated OS.<\/jats:p>","DOI":"10.1038\/s41598-022-09745-1","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:03:13Z","timestamp":1649246593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient demographics, clinicopathologic features, and outcomes in wild-type gastrointestinal stromal tumor: a national cohort analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Tahsin M.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Verbus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"9745_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577\u2013580. https:\/\/doi.org\/10.1126\/science.279.5350.577 (1998).","journal-title":"Science"},{"key":"9745_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708\u2013710. https:\/\/doi.org\/10.1126\/science.1079666 (2003).","journal-title":"Science"},{"key":"9745_CR3","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano, C. & George, S. Gastrointestinal stromal tumor: Challenges and opportunities for a new decade. Clin. Cancer Res. 26, 5078\u20135085. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1706 (2020).","journal-title":"Clin. Cancer Res."},{"key":"9745_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/JCO.2016.68.6733","volume":"35","author":"CB Weldon","year":"2017","unstructured":"Weldon, C. B. et al. Surgical management of wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health Pediatric and wildtype GIST clinic. J. Clin. Oncol. 35, 523\u2013528. https:\/\/doi.org\/10.1200\/JCO.2016.68.6733 (2017).","journal-title":"J. Clin. Oncol."},{"key":"9745_CR5","doi-asserted-by":"publisher","first-page":"268177","DOI":"10.1126\/scitranslmed.3009961","volume":"6","author":"JK Killian","year":"2014","unstructured":"Killian, J. K. et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci. Transl. Med. 6, 268177. https:\/\/doi.org\/10.1126\/scitranslmed.3009961 (2014).","journal-title":"Sci. Transl. Med."},{"key":"9745_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/ejhg.2013.80","volume":"22","author":"MA Pantaleo","year":"2014","unstructured":"Pantaleo, M. A. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT\/PDGFRA wild-type GIST. Eur. J. Hum. Genet. 22, 32 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"9745_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos, S. A. et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health gastrointestinal stromal tumor clinic. JAMA Oncol. 2, 922\u2013928. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256 (2016).","journal-title":"JAMA Oncol."},{"key":"9745_CR8","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1097\/PAS.0b013e3182260752","volume":"35","author":"M Miettinen","year":"2011","unstructured":"Miettinen, M. et al. Succinate dehydrogenase-deficient GISTs: A clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am. J. Surg. Pathol. 35, 1712\u20131721. https:\/\/doi.org\/10.1097\/PAS.0b013e3182260752 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"9745_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich, M. C. et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: Analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol. 3, 944\u2013952. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6728 (2017).","journal-title":"JAMA Oncol."},{"key":"9745_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368, 1329\u20131338. https:\/\/doi.org\/10.1016\/S0140-6736(06)69446-4 (2006).","journal-title":"Lancet"},{"key":"9745_CR11","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","volume":"30","author":"S George","year":"2012","unstructured":"George, S. Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J. Clin. Oncol. 30, 2401 (2012).","journal-title":"J. Clin. Oncol."},{"key":"9745_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamasurg.2016.5047","volume":"152","author":"KE Fero","year":"2017","unstructured":"Fero, K. E. et al. Surgical management of adolescents and young adults with gastrointestinal stromal tumors: A US population-based analysis. JAMA Surg. 152, 443\u2013451. https:\/\/doi.org\/10.1001\/jamasurg.2016.5047 (2017).","journal-title":"JAMA Surg."},{"key":"9745_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030730","author":"NS Ijzerman","year":"2020","unstructured":"Ijzerman, N. S. et al. Gastrointestinal stromal tumours (GIST) in young adult (18\u201340 years) patients: A report from the Dutch GIST Registry. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12030730 (2020).","journal-title":"Cancers (Basel)"},{"key":"9745_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02528-y","author":"JA Fernandez","year":"2021","unstructured":"Fernandez, J. A. et al. Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: A comparative study with gastric GISTs. Clin. Transl. Oncol. https:\/\/doi.org\/10.1007\/s12094-020-02528-y (2021).","journal-title":"Clin. Transl. Oncol."},{"key":"9745_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00384","author":"EA Makris","year":"2021","unstructured":"Makris, E. A. et al. Synchronous, yet genomically distinct, GIST offer new insights into precise targeting of tumor driver mutations. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00384 (2021).","journal-title":"JCO Precis Oncol."},{"key":"9745_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1221","author":"AK Sharma","year":"2021","unstructured":"Sharma, A. K. et al. Location of gastrointestinal stromal tumor (GIST) in the stomach predicts tumor mutation profile and drug sensitivity. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1221 (2021).","journal-title":"Clin. Cancer Res."},{"key":"9745_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0973","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. KIT(low) cells mediate imatinib resistance in gastrointestinal stromal tumor. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0973 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"9745_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1245\/s10434-008-9969-z","volume":"15","author":"BK Goh","year":"2008","unstructured":"Goh, B. K. et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann. Surg. Oncol. 15, 2153\u20132163. https:\/\/doi.org\/10.1245\/s10434-008-9969-z (2008).","journal-title":"Ann. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09745-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:04:26Z","timestamp":1669338266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9745"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09745-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5774"}}